Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?

NCT07711548 · Not yet recruiting

Last updated 2026-07-28

This clinical trial is testing whether two different diet plans can help adults with overweight or obesity maintain their weight loss for 12 months after completing GLP-1 therapy.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) study

Participants 292 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2027-03 · est. completion 2030-04

What this study is testing ClinicalTrials.gov NCT07711548 ↗

Description as written by the study sponsor.

So far, treatment with semaglutide (Wegovy) for therapy of obesity demonstrates substantial effects. However, most patients do not desire life-long pharmaceutical therapy or discontinue this treatment regime. This is accompanied by rapid weight regain. Moreover, numerous patients are open to an intermittent therapy. This trial aims to investigate whether two diet interventions can keep weight stable after weight loss with semaglutide in people with obesity or overweight.

Treatments tested

NutriAct plus Behavioral

Dietary pattern, vegetarian version of the NutriAct pattern
Rescue VLCD Behavioral

Very low calorie diet as full meal replacement over 28 days in case of weight regain

Main thing measured	weight in kg
Sponsor	Knut Mai
Conditions studied	Obesity & Overweight, Weight Loss Maintenance
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07711548 ↗